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Abstract 
The inherent hydrophobicity of membrane proteins is a major barrier to membrane protein research 
and understanding. Their low stability and solubility in aqueous environments coupled with poor 
expression levels make them a challenging area of research. For many years the only way of working 
with membrane proteins was to optimise the environment to suit the protein, through the use of 
different detergents, solubilising additives, and other adaptations. However, with innovative protein 
engineering methodologies the membrane proteins themselves are now being adapted to suit the 
environment. This mini review looks at the types of adaptations which are applied to membrane 
proteins from a variety of different fields, including; water solubilising fusion tags, thermostabilising 
mutation screening, scaffold proteins, stabilising protein chimeras, and isolating water soluble 
domains.  
 
Introduction 
Proteins tend to be classified into one of two broad categories, globular cytoplasmic proteins, and 
integral membrane proteins (IMPs)[1]. This simple classification is defined by a proteins intrinsic 
ability to produce a stable, functional structure in either a hydrophilic or hydrophobic environment. 
Analysis of published genomes suggests that between 15% and 30% of the identified open reading 
frames encode proteins which would fit into the latter, membrane embedded, category[2,3]. Yet, despite 
seemingly so many membrane proteins available, these hydrophobic proteins lag significantly behind 
their water soluble counterparts in terms of characterisation[4]. For instance, less than 1% of the 
resolved protein structures deposited in the Protein Data Bank (PDB) are membrane proteins[5]. This 
statistic belies the significant effort and strides made in membrane protein research over the past 
decades.   
Understanding a protein in terms of function, usually requires an understanding of its three 
dimensional structure, and the current paucity of membrane protein structures produces a knowledge 
gap which has an impact on a variety of research areas in which membrane proteins play a key role[3].  
For instance, membrane proteins are prime targets for therapeutics due to their important roles as key 
mediators of molecular transport into and out of the cell, as well in other crucial processes such as cell 
signalling[6]. The knowledge gap in membrane protein research is a major bottleneck to the 
development of future biomedical and biotechnological advances.  
The main barrier to accelerated membrane protein research is their intrinsic hydrophobicity. This 
single factor produces difficulties at every stage of the protein production pipeline[3]. Membrane 
proteins have, by their very nature, a predominance of alkyl and aryl residues on their surface which 
make hydrophobic interactions with the surrounding lipid. This hydrophobic interaction is the main 
driver of their folding and stability in the lipid environment. Most analytical, characterisation, and 
structural techniques, such as X-ray crystallography, NMR, and to an increasing extent electron 
microscopy, rely on relatively large quantities of protein which are soluble in aqueous conditions[3]. 
As most membrane proteins are produced at very low levels in their natural host, they are difficult to 
isolate from native membranes. High levels of expressed protein in easily amplified cells such as E. 
coli, which can then be adequately solubilised, is a necessity.  
Expressed membrane proteins must be incorporated into the cell membrane so that they assume the 
correct fold and retain their functional state. Such a small amount of available membrane relative to 
the total available volume within the cell places a limitation on the amount of viable membrane 
protein that any cell can produce. In addition, many membrane proteins produce large insoluble 
aggregates, inclusion bodies, within the cytoplasm. In order to maximise the amount of the target 
protein in the membrane, the expression conditions (typically host strain, growth medium, induction 
temperature and duration) will require extensive time consuming optimisation to achieve sufficient 
levels of protein for downstream processing[7], and in many cases this may never be realised. This is 
especially true for membrane transporters. Overexpression of transport proteins can produce an 
unwanted increase in the movement of molecules and ions across the cell membrane, causing 
significant toxicity and a reduction in culture growth and protein yield.  
Membranes, harbouring the target protein, must be harvested from a cell lysate and solubilised so that 
they can be purified under aqueous conditions. Conventional solubilisation strategies focus on the 
addition of detergents[8±10]. These amphiphilic molecules self-assemble in solution, forming micelle 
structures which can encompass the membrane proteins, burying the hydrophobic surface residues in 
the FRUHRIWKHPLFHOOHDQGPDLQWDLQLQJWKHSURWHLQ¶VVWUXFWXUHFORVHWRWKDWSUHVHQWLQWKHQDWXUDOOLSLG
environment[11]. Finding a detergent which offers good levels of solubilisation whilst retaining the 
proteins structure requires painstaking optimisation and trial and error testing of a range of detergents 
with different chain lengths and head groups[9,12,13].  In addition, the pH of the buffer, salinity levels, 
and the presence or absence of various other additives will all play a role in determining the final 
stability of the membrane protein[13,14].  A protein which is only stable and functional in a narrow 
window of environmental conditions is not only difficult to handle and characterise in the laboratory, 
but also curbs its potential use in biomedical or biotechnological applications. New additives to 
replace the use of detergents, such as nanodiscs[15,16], SMALPs[17], bicelles[18] and lipid like peptides 
(LLP)[19] are now emerging.  
With the advent of modern genetic engineering techniques and the ability to alter genetic sequences 
easily and cheaply, there are ways to overcome many of these challenges for membrane protein 
production by manipulating the protein itself. This mini review looks at some of the options available 
and provides examples of where changes to the membrane protein itself have been used with excellent 
results.  
 
Isolating water soluble domains from a membrane protein. 
One approach to the investigation of membrane proteins is to decide if the membrane spanning region 
of the protein is actually required at all. Many membrane proteins possess water soluble domains 
which may be exposed to the cytoplasm, periplasm or even extracellularly. These domains are often 
sites of catalytic activity. The activity of such domains can provide an easily assayable function for 
structure-function investigations. Working on a water soluble domain overcomes many of the inherent 
challenges of membrane proteins, with improved expression levels, greater stability and ease of 
characterisation. A recent example of a truncated membrane protein investigated in this way is the 
phosphoethanolamine transferase MCR-1 from Enterobacteriaceae[20]. The crystal structure of this 
protein is helping to elucidate the mechanisms behind certain antibiotic resistance.   
From a protein design perspective, the biggest obstacle is correctly determining the domain 
boundaries. This is a straightforward procedure where sequence alignments to well characterised 
protein families exist. However, for some protein groups this can be anything but a trivial exercise.  
Truncating the protein too early may remove stabilising residues, and too late may mean additional, 
potentially destabilising residues are fused to the domain of interest. High throughput solubility 
screening strategies can help. The expression of soluble proteins by random incremental truncation 
(ESPRIT) is one such method[21]. This library based approach, requiring very little background 
knowledge of the protein of interest, uses robotic screening to analyse potentially thousands of clones.  
In essence the gene encoding the protein of interest is enzymatically degraded, a nucleotide at a time, 
to produce a spectrum of sequences which become incrementally smaller[21]. Each library member is 
fused to sequences encoding a C-terminal biotin acceptor peptide [22] and an N-terminal poly-histidine 
tag. The biotinylation peptide acts as a solubility reporter, as soluble proteins will be efficiently 
biotinylated in vivo. Only proteins displaying both a positive signal for the N and C terminal tags will 
be (a) soluble, (b) in the desired reading frame, and (c) free from proteolytic degradation[21] (Figure 
1A). The ESPRIT methodology was used to investigate the phosphatase domain of the sporulation 
protein SpoIIE from Bacillus subtilis [23]. SpoIIE has an N-terminal membrane spanning domain with 
ten transmembrane helices (Figure 1B). The remainder of the protein is displayed to the inside of the 
spore compartment during stage III of the sporulation pathway, where it forms part of a sigma factor 
cascade, enabling the spore and mother cell compartments to establish different fates[24,25]. By 
truncating the spoIIE gene incrementally, the domain boundaries were isolated and soluble protein 
purified, something that was difficult to achieve from analysis of the sequence alone[23] (Figure 1B). 
Based on this technique the crystal structure of a domain swapped dimer of the phosphatase was 
determined Figure 1C), confirming it belonged to the PP2C family of protein phosphatases, and 
allowed an intramolecular signalling surface to be identified[26]. 
 
 
Figure 1. (A) A portion of the high throughput screening array of SpoIIE truncation mutants. (B) The 
SpoIIE protein with soluble constructs indicated and residue positions marked. Dashed boxes 
highlight the SRVWXODWHG GRPDLQ ERXQGDULHV Į-į & &DUWRRQ DQG VSDFH ILOOLQJ PRGHOV RI 6SR,,(
domain swapped dimer, coloured cyan and orange. Figure adapted from Rawlings et al[23] and 
Levdikov et al with permission[26]. 
 
 
Producing water soluble IMPs with solubilising fusion tags. 
A recent development in membrane protein engineering is to retain the native membrane protein 
sequence, but introduce a fusion tag which overcomes the insolubility of the membrane protein in 
aqueous solution[27]. Mizrachi et al have pioneered such an approach [28,29], termed SIMPLEx 
(solubilisation of IMPs with high levels of expression). They employ an amphipathic protein fusion 
partner, added to the membrane protein termini[29]. In this case the C-terminal lipid binding domain of 
apolipoprotein was selected due its intrinsic amphipathic nature, and its inherent structural 
flexibility[30]. To prevent undesired incorporation of the membrane protein in the inner cell membrane 
of E. coli a decoy protein, such as maltose binding protein (MBP) was added to the N-termini of the 
IMP. Having such a large soluble protein at the N-termini blocks transfer of the IMP to the 
membrane, ensuring efficient solubilisation via the apolipoprotein fusion tag[29]. Using this 
methodology, a range of different IMPs have been produced without the need for additional 
solubilising additives (detergents for example). The list of IMPs currently explored with this 
technique extends to cytochrome B5, the ethidium multidrug resistance protein E (EmrE), Claudin-1 
and Claudin-3, DsbB and OmpX[29]. Significantly, IMPs from both bacterial and mammalian systems 
have been tested with equal success[29]. However, careful characterisation is required to ensure that the 
membrane protein retains the correct structure and function, and that it has not been unintentionally 
compromised by the addition of the solubilising tag. The ability to produce human IMPs in this way 
opens up the approach for drug discovery applications, where the challenges of producing adequate 
quantities of purified membrane protein is a major hurdle[31]. 
The implications of this methodology have wider applications. For instance, the SIMPLEx approach 
has been used to produce a water soluble form of the bacterial protein DsbB[29,32]. This enzyme, in the 
presence of ubiquinone, is capable of catalysing the oxidation of the thiodisulphide oxidoreductase 
partner enzyme DsbA within the bacterial periplasm[33][34] (Figure 2A). DsbA is exported to the 
periplasmic space via a defined N-terminal export sequence. DsbB is a membrane bound enzyme 
which inserts into the inner membrane and thereby limits the oxidising activity of the protein to the 
periplasm. By producing a water soluble form of DsbB via the addition of the apolipoprotein and 
decoy fusion tags, this protein can be overexpressed to high levels within the cytoplasm[32].  In that 
study the partner protein, DsbA, had its periplasmic export sequence removed, meaning it too was 
retained within the cytoplasm[32].   This allowed the DsbB-DsbA disulphide bond catalysis pathway, 
which was previously limited to the periplasm, to be fully constituted within the cytoplasm.  The 
modified form of DsbB was still able to interact with DsbA as shown by crosslinking and small angle 
X-ray scattering (SAXS) studies (Figure 2B)[32]. The recompartmentalisation of this pathway in the 
cytoplasm was also enzymatically active, displaying disulphide bond forming capability against 
several different substrate proteins[32]. Excitingly, this result demonstrates that by engineering IMPs in 
this way, enzymatic activities previously only associated with lipid membranes, can be transplanted 
into different cellular compartments and non-native environments without the need for additional 
solubilising additives.  
 
Figure 2. (A) The reconstituted cytoplasmic DsbA/DsbB system. DsbB is solubilised via ApoAI* and 
the decoy protein MBP. (B) SAXS model of the DbsB-ApoAI*-MBP construct in blue, with the 
DsbA bound form in red. Crystals structures of the various components have been used to produce 
models of the fusion protein to fit the SAXS structure (PDB accession numbers for the structures used 
are: 2K74 for monomeric DsbB, 2LEG for the complex DsbA/DsbB, 2A01 for ApoAI, and 1NL5 for 
MBP). Figure adapted from Mizrachi et al[32] with permission. 
 
A slightly different approach to generate water soluble membrane proteins is via the introduction of 
multiple residue substitutions, where typically hydrophobic surface residues are switched for 
hydrophilic ones. This approach is often guided by computational modelling in order to pick the most 
appropriate substitutions, and has been successfully used to generate various water soluble forms of 
membrane proteins including KcsA[35] and the Ca2+ pump regulating protein phospholamban[36,37].  
 
Conformational thermostabilisation of GPCRs.  
One of the highest priority IMP classes for structural and biophysical characterisation are G protein-
coupled receptors (GPCRs). These proteins are found within the membranes of eukaryotic cells[38]. 
GPCRs are involved in a huge array of different cellular processes. 7KHVH ,03¶V feature seven 
transmembrane spanning helices (TMS) which enable signal transduction across a cell membrane [39]. 
These proteins feature specific binding sites for ligands, which stimulates the GPCR[40]. The 
interacting ligands which activate the receptors can be the natural receptor molecule or a synthetic 
ligand. This ability to elicit a GPCR response with synthetic molecules makes these proteins prime 
targets for pharmaceuticals[41], and they represent the site of action for approximately 35% of existing 
drugs[42]. 
One of the main difficulties in realising more GPCR crystal structures is the inherent structural 
flexibility in these proteins[43]. They display a highly dynamic structure, with a large degree of 
conformation flexibility[44]. For a protein to crystallise it needs to assume a regular, ordered assembly 
of repeating protein units. Flexibility within the protein structure means each protein has the potential 
to assume one of a large number of possible conformations; this makes the crystals unlikely to form or 
have the long range order required for X-ray diffraction studies. An additional problem to overcome is 
WKDW*3&5¶VRIWHQKDYHTXLWHVKRUW ORRSVFRQQHFWLQJ WKHGLIIHUHQW WUDQVPHPEUDQHVSDQQLQJKHOLFHV
The lack of significant hydrophilic regions means a shortage of protein-protein contacts in the crystal 
lattice, leading to instability of the protein crystal and poor diffraction quality. However, there are 
protein engineering methodologies which can help in both of these regards[43]. 
An innovative approach is termed conformational thermostabilisation. This methodology has the 
ability to produce a stabilised GPCR with a favoured conformation, making it ideal for crystallisation 
and structural characterisation[43,45]. This technique relies on a program of single residue substitutions, 
typically switched to alanine, systematically introduced at each position along the protein 
sequence[46][47]. Each variant is then expressed in cells, detergent solubilised, and heated to just above 
the melting temperature (Tm) of the native protein. Using a radiolabelled version of a ligand which 
binds to the GPCR, allows researchers to easily and rapidly determine if the radioligand remains 
bound to the detergent solubilised protein after heating. This technique relies on the fact that the 
ligand binding site of GPCRs tends to be formed from residues displayed on various parts of the 
protein[40]. If the protein is heated and subsequently denatures, the specific architecture of the protein 
responsible for producing the binding site would be lost[48]. Therefore binding/non-binding of the 
specific radioligand gives a very convenient indicator of thermostability.  
Preparing, expressing and screening these mutations (potentially hundreds of constructs for a single 
GPCR) is a large undertaking, but using high throughput techniques and automation where necessary 
can reduce some of the experimental burden[46]. An alternative strategy is to generate random 
mutations by processes such as error prone PCR and screen for binding on the pool of variants using 
fluorescent ligands and fluorescently activated cell sorting (FACS) equipment[49,50]. In both cases, by 
determining the individual substitutions which give rise to the largest increase in Tm, the most 
stabilising mutations can be collected within a single construct. However, the most elegant addition to 
this procedure is the use of a specific agonist or antagonist during the thermal screening steps in order 
to find mutations which stabilise the protein in an active or inactive state. There are challenges to this 
technique, namely that it requires functional well expressing membrane proteins, as well as ready 
access to a specific ligand, and the infrastructure to produce and screen a high number of
residue substitutions (hundreds of constructs in most cases). However, the rewards appear to be make 
up for these difficulties with numerous examples of structures obtained through this approach[51±55].  
Computational advances are also helping to lighten the load of some of these limitations. Using 
different strategies ranging from free energy calculations to machine learning, allows a suite of 
candidate mutations to be rapidly screened for stability in silico[56,57]. To reduce the range of potential 
mutants most systematic mutagenesis strategies only substitute each residue for alanine but it has been 
estimated that in around 30% of cases alanine may not produce the optimum stabilization[47]. A 
computational approach allows each residue to be swapped for any desired amino acid, thereby 
allowing much greater mutational scope to be explored. Computational methodologies appear 
extremely promising, particularly with the increase in GPCR structures from which to build realistic 
homology models.  Due to the reductions in both cost and time it can bring, many laboratories not 
equipped for high throughput screening would have the potential to benefit from a thermostabilising 
methodology. 
Stabilisation through protein chimeras. 
GPCRs, due to their prevalence as therapeutic drug targets, are at the forefront of membrane protein 
innovations. Over the past decade various teams of researchers have made chimeric proteins, whereby 
a loop connecting two transmembrane spanning helices is exchanged for a stable, soluble, protein[58±
60]
. By incorporating the new protein into the IMP a significant increase in hydrophilicity is achieved. 
If chosen carefully, the new fusion partner can promote the formation of protein crystals. Key 
requirements for judicious selection of fusion partners are; that the protein is extremely stable, is 
already structurally characterised, and that the N and C termini are located closely together to allow 
them to be inserted into a loop of an IMP without distorting the arrangement of the transmembrane 
helices. A recent example of this is the Orexin receptor, OX2R[58]. This GPCR is a member of the 
rhodopsin family and forms part of the sleep-wake cycle in mammals where it binds to neuropeptides 
of the central nervous system[61]. Yin et al prepared a chimera of OX2R by substituting the 
interconnecting loop 3 (IL3) with PGS, a glycogen synthase from Pyrococcus abysii[58]. This 196 
residue protein is extremely stable, as it is derived from a thermophilic organism, benefitted from a 
high resolution crystal structure, and featured termini less than 10 Å apart. The chimeric protein was 
crystallised and yielded a crystal structure of OX2R at 2.5 Å resolution[58]. The binding interaction 
with the anti-insomnia drug Suvorexant was revealed, and novel potential binding sites for future 
agonists were identified via computational docking to the OR2X model[58]. A limitation of this 
approach is that the protein is missing one loop which may have unintended consequences for protein 
conformation or ligand interaction. This is often minimised by selecting loops which are less likely to 
form part of the ligand binding site.  
  
Figure 3. (A) Cartoon structure of the OX2R±PGS fusion protein. The PGS domain is indicated in 
grey and is located at interconnecting loop 3. The Suvorexant ligand is depicted as spheres and 
coloured green for carbon, red for oxygen, and blue for nitrogen. (B) Packing of OX2R±PGS in the 
crystal lattice. Note, many of the crystal contacts occur through the PGS domain[58]. Figure prepared 
using PyMOL[62]. 
Membrane protein chimeras with green fluorescent protein (GFP) have been used to find membrane 
protein constructs with improved stability, expression, or membrane insertion[63±67]. The intrinsic 
fluorescence of GFP makes it a natural choice of reporter protein, which can be easily assayed using 
fluorescence detection. In these cases GFP (or a form of split GFP to minimise any stabilising effect 
from the GFP itself) is typically fused to one of the termini of the membrane protein, allowing the 
protein to be tracked during various stages of its production and purification. This approach can, for 
instance, be coupled to targeted or random mutagenesis of the protein to find variants with improved 
expression levels and detergent stability[63,67].  
If the part of the membrane protein which is of interest is one of the interconnecting loop regions and 
the transmembrane spanning portion is simply an anchor, then there are opportunities to transplant the 
desired loop and graft it onto a scaffold protein. This approach has been used to investigate the loop 
regions of bacterial membrane proteins from Magnetotactic bacteria (MTB). These bacteria are able 
to produce crystals of magnetic iron minerals (magnetite or goethite) within specialised membrane 
bound organelles in their cells termed magnetosomes[68±70]. The magnetosomes harbour a range of 
different proteins, embedded within the membrane, which enable the production of the crystals[71,72]. 
Some of these proteins are found tightly bound to the crystal, interacting via the loops between 
transmembrane spanning helices. In one example the loop region from MamC was transplanted onto 
maltose binding protein (MBP)[73]. This allowed the crystal structure of the loop to be obtained that 
revealed a helical conformation, from which a proposed magnetite interaction site was derived[73]. 
Protein produced using this approach was tested in in vitro magnetite formation reactions to ascertain 
whether this construct retained their native functionality. Inspection of the synthesised magnetite 
nanocrystals showed these proteins were able to influence the properties of synthetic magnetite 
nanoparticles[73]. 
 
Conclusions 
Membrane proteins are some of the most challenging biomolecules to produce, isolate and 
characterise, and yet they often perform some of the most interesting and useful roles within the 
protein function repertoire. This makes them a rich source of reagents for use in fields as wide ranging 
as pharmaceuticals to nanoparticle formation. Their inherent hydrophobicity and stability within lipid 
environments creates obstacles to their wider use and exploitation. However, advances within the field 
of protein engineering are providing new tools to overcome these difficulties. Proteins can be edited 
to yield water soluble domains[23], fused to solubilising protein tags to produce water soluble 
variants[29], or have their stability enhanced to aid in crystallisation or detergent compatibility[46]. The 
ingenuity of protein engineers has led to many new innovations and it is truly an exciting time to be 
working in the area of membrane protein research.  
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